Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments

Abstract Alzheimer's disease (AD) is associated with characteristic and progressive reductions in flourodeoxyglucose positron emission tomography (FDG PET) measurements of the regional cerebral metabolic rate for glucose. These reductions begin years before the onset of symptoms, are correlated...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurobiology of aging 2011-12, Vol.32 (Suppl 1), p.S44-S47
1. Verfasser:	Reiman, Eric M
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer Disease - diagnostic imaging Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer's disease Biomarkers Brain - diagnostic imaging Brain - metabolism Brain imaging Cerebrospinal fluid Clinical trials Clinical Trials as Topic Dementia Endpoint Determination Fluorine Radioisotopes Fluorodeoxyglucose F18 Glucose - metabolism Humans Internal Medicine Magnetic resonance imaging Mild cognitive impairment Neurology Positron emission tomography Preclinical Presymptomatic Prevention Radiopharmaceuticals Treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!